The hardware and bandwidth for this mirror is donated by METANET, the Webhosting and Full Service-Cloud Provider.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]metanet.ch.
Design and analysis tools for target trial emulation using longitudinal observational data. Functions are provided for checking person-period data, expanding longitudinal data into sequentially nested trials, estimating inverse probability weights for intention-to-treat and per-protocol analyses, and assessing weight distributions and covariate balance. Additional functions fit weighted pooled discrete-time outcome models, obtain standardized risks and treatment contrasts, and estimate weighted Kaplan-Meier and Aalen-Johansen curves. Two worked examples based on fully synthetic data illustrate an active-comparator new-user study comparing sodium-glucose cotransporter 2 inhibitors with dipeptidyl peptidase-4 inhibitors and an analysis of sequentially nested trials comparing angiotensin receptor blocker and calcium channel blocker strategies.
| Version: | 1.1.1 |
| Depends: | R (≥ 4.1.0) |
| Imports: | graphics, nnet, sandwich, stats, utils |
| Suggests: | testthat (≥ 3.0.0) |
| Published: | 2026-08-02 |
| DOI: | 10.32614/CRAN.package.TTE |
| Author: | Hisashi Noma |
| Maintainer: | Hisashi Noma <noma at ism.ac.jp> |
| License: | GPL-3 |
| NeedsCompilation: | no |
| Materials: | NEWS |
| CRAN checks: | TTE results |
| Reference manual: | TTE.html , TTE.pdf |
| Package source: | TTE_1.1.1.tar.gz |
| Windows binaries: | r-devel: TTE_1.1.1.zip, r-release: TTE_1.1.1.zip, r-oldrel: TTE_1.1.1.zip |
| macOS binaries: | r-release (arm64): TTE_1.1.1.tgz, r-oldrel (arm64): TTE_1.1.1.tgz, r-release (x86_64): TTE_1.1.1.tgz, r-oldrel (x86_64): TTE_1.1.1.tgz |
Please use the canonical form https://CRAN.R-project.org/package=TTE to link to this page.
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.